- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| Mo | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 27.09. | New to The Street to Broadcast Saturday, September 27th Featuring NeOnc Pharma $NTHI and Other Innovative Companies | 415 | ACCESS Newswire | Bloomberg Television 6:30 PM ET as Sponsored Programming - With TV Commercials Debuting by Laser Photonics $LASE, Synergy CHC $SNYR, Sustainable Green Team $SGTM, and Acurx Pharmaceuticals $ACXP NEW... ► Artikel lesen | |
| 22.09. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on "Health Uncensored with Dr. Drew" on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ... | 1 | GlobeNewswire (USA) | ||
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 11.09. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09. | FDA authorizes NeOnc to advance brain cancer drug to phase 2 trials | 1 | Investing.com | ||
| 10.09. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 - A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer | 103 | GlobeNewswire (Europe) | CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering... ► Artikel lesen | |
| 25.08. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board | 1 | GlobeNewswire (USA) | ||
| 22.08. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.08. | NeOnc Technologies Holdings GAAP EPS of $0.30 | 2 | Seeking Alpha | ||
| 19.08. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update | 528 | GlobeNewswire (Europe) | CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering... ► Artikel lesen | |
| 18.08. | NEONC TECHNOLOGIES HOLDINGS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 18.08. | Fehler bei RSU-Verbuchung: NeOnc Technologies muss Finanzzahlen für Q1 2025 revidieren | 1 | Investing.com Deutsch | ||
| 14.08. | NEONC TECHNOLOGIES HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 13.08. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | NeOnc secures $50 million investment following UAE subsidiary formation | 1 | Investing.com | ||
| 11.08. | New to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation | 413 | ACCESS Newswire | CALABASAS, CA AND ABU DHABI, UAE / ACCESS Newswire / August 11, 2025 / NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for... ► Artikel lesen | |
| 11.08. | NeOnc secures $50 million investment as UAE subsidiary incorporation completes | 3 | Investing.com | ||
| 11.08. | NeOnc sichert sich 50-Millionen-Dollar-Investment nach Gründung von Tochtergesellschaft in den VAE | 3 | Investing.com Deutsch | ||
| 11.08. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation | 2 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
| CG ONCOLOGY | 39,820 | -0,09 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
| IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts | ||
| JANUX THERAPEUTICS | 24,000 | +3,05 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,310 | +0,29 % | ARS Pharma secures $250M loan to accelerate Neffy rollout | ||
| BIONTECH | 90,45 | +0,06 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,770 | -2,25 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 8,470 | +13,54 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| EVOTEC | 6,744 | +2,00 % | Sonntag-Meldung zu EVOTEC SE: Jetzt zählt jede Minute! | ||
| LENZ THERAPEUTICS | 48,740 | +0,87 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,18 | +10,89 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 47,010 | +6,41 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |
Das Unternehmen NEONC TECHNOLOGIES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,130 (+1,14 %) liegt der Kurs bei 11,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.